Drugs for children - a turning point in European law
Keywords:
medicines for children, pharmaceutical industry, drug trialsAbstract
New EU proposals on medicines for children, becoming effective end of 2006 are presented in this paper. This will create a new situation for pediatric patients, doctors and pharmaceutical industry, since nearly 50% of medicines registered in Europe are currently used “off-label” when prescribed for children aged 0–18.
Downloads
References
www.fda.gov/cder/pediatric/summaryreview.htm
www.emea.eu.int/
www.ich.org/
www.heads.medagencies.org/
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2005 Medical Journal of the Rzeszow University
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
